COMPANY

Pulmotect

HQ: Houston, TX source · pulmotect.com ↗ · Southwest

Keywords: respiratory inhaled oncology pneumonia COVID-19 asthma Hematologic Malignancies Hematopoietic Stem Cell Transplant Hematologic Diseases Stem Cell Transplants COPD PUL-042

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)10NIH grants

Timeline

Jun 27, 2025 Trial start Phase 2: PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) source ↗
2024-12 Trial start Phase 1: A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients source ↗
Jun 16, 2020 Trial start Phase 2: The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection source ↗
Jun 9, 2020 Trial start Phase 2: The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 source ↗
Jan 21, 2019 Trial start Phase 2: The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD source ↗
2015-07 Trial start Phase 1: Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042) source ↗
2014-02 Trial start Phase 1: Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects source ↗

Upcoming milestones

2027-04 (ESTIMATED) · Phase 2 · PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) · NCT06665100

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT06665100	PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)	Phase 2	Recruiting	Jun 27, 2025	2027-04 (estimated)
NCT04313023	The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2	Phase 2	Completed	Jun 9, 2020	Jul 31, 2021 (actual)
NCT03097796	A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients	Phase 1	Withdrawn	2024-12	2026-03 (estimated)
NCT04312997	The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection	Phase 2	Completed	Jun 16, 2020	Jul 2, 2021 (actual)
NCT03794557	The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD	Phase 2	Completed	Jan 21, 2019	Dec 16, 2020 (actual)
NCT02566252	Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)	Phase 1	Completed	2015-07	2016-01 (actual)
NCT02124278	Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects	Phase 1	Completed	2014-02	2014-10 (actual)

NIH awards 10

Annual award amounts. Total $7.0M.

May 31, 2017 NIH award 5R44HL127677-06 FY2017: $998,771 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Expanding the Market and Success Rates for Myeloabla source ↗
Apr 22, 2016 NIH award 5R44HL127677-05 FY2016: $998,771 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Expanding the Market and Success Rates for Myeloabla source ↗
Feb 19, 2016 NIH award 2R44HL118926-02 FY2016: $999,372 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Preventing and treating RSV pneumonia in immunocompr source ↗
Apr 30, 2015 NIH award 9R44HL127677-04 FY2015: $982,488 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Expanding the Market and Success Rates for Myeloabla source ↗
Jul 14, 2014 NIH award 2R44HL115903-02 FY2014: $985,628 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Preventing asthma exacerbations by reducing viral re source ↗
Feb 6, 2014 NIH award 1R43HL118926-01A1 FY2014: $231,348 awarded for that fiscal year; activity R43 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Boosting the innate immune system of the lungs to source ↗
Dec 20, 2013 NIH award 5R44AI092904-03 FY2014: $308,146 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Rapidly boosting innate immunity in the lungs to pro source ↗
Jan 11, 2013 NIH award 2R44AI092904-02A1 FY2013: $997,525 awarded for that fiscal year; activity R44 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Rapidly boosting innate immunity in the lungs to p source ↗
Aug 20, 2012 NIH award 1R43HL115903-01 FY2012: $301,296 awarded for that fiscal year; activity R43 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Preventing asthma exacerbations by reducing viral re source ↗
Jan 25, 2011 NIH award 1R43AI092904-01 FY2011: $221,748 awarded for that fiscal year; activity R43 (SBIR); PI SCOTT, BRENTON; recipient as written: PULMOTECT, INC, HOUSTON, TX. Rapidly boosting innate immunity in the lungs to pro source ↗